NasdaqCM:DNTHBiotechs
Dianthus Therapeutics (DNTH) Is Up 19.4% After Early CAPTIVATE GO Decision And $719M Raise
Dianthus Therapeutics recently reported an early GO decision in its Phase 3 CAPTIVATE trial of claseprubart for CIDP, after achieving 20 confirmed responders ahead of the planned interim analysis and confirming a favorable safety profile through independent DSMB review.
On the heels of these clinical results, the company completed a large follow-on public equity offering of common stock and pre-funded warrants, raising roughly US$719,000,000 to support ongoing trials, commercial readiness,...